Načítá se...

Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets

The development of pulmonary arterial hypertension (PAH) in pediatric patients has been linked to the production of the arachidonic acid metabolite, thromboxane A(2) (TxA(2)). The present study evaluated the therapeutic effect of furegrelate sodium, a thromboxane synthase inhibitor, on the developme...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hirenallur-S., Dinesh K., Detweiler, Neil D., Haworth, Steven T., Leming, Jeaninne T., Gordon, John B., Rusch, Nancy J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Medknow Publications & Media Pvt Ltd 2012
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3401873/
https://ncbi.nlm.nih.gov/pubmed/22837860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2045-8932.97605
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!